Drug intelligence / Profile preview

AMI-918

Development stage: Preclinical
Lead developer: Cytotheryx
Modality: Cell Therapies

Overview

**AMI-918** is an allogeneic, off-the-shelf hepatocyte cell therapy developed by Ambys Medicines to restore lost hepatic function in patients with liver disorders. It is designed as an on-demand treatment for acute liver failure settings, potentially addressing up to 100,000 U.S. patients with acute liver disease and expandable to chronic liver disease populations of nearly 500,000. The therapy leverages Ambys's proprietary platform for scalable manufacturing of functional human hepatocytes, with plans to enter clinical trials around 2023; a follow-on program aims to enhance cell durability and eliminate the need for immunosuppression.[1][3][5][7]

Beyond the preview

Go deeper on AMI-918.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMI-918.

Explore the full profile